Table 1 Patient demographics and preoperative medications
Variable | GHM N (%), mean (SD), or median [Q1, Q3] | CHMN (%), mean (SD), or median [Q1, Q3] | P value |
|---|---|---|---|
Demographic data (N = 80, respectively) | |||
Age (mean ± SD) | 63.62 ± 7.1 | 63.1 ± 7.3 | 0.649 |
Sex | |||
Men (n, %) | 62 (77.5) | 61 (76.3) | 0.500 |
Women (n, %) | 18 (22.5) | 19 (23.7) | |
BMI (kg/m2, mean ± SD) | 24.5 ± 3.5 | 24.6 ± 3.1 | 0.838 |
Hypertension (n, %) | 42 (52.5) | 48 (60.0) | 0.505 |
Diabetes mellitus (n, %) | 38 (47.5) | 44 (55.0) | 0.508 |
Chronic kidney disease (n, %) | 14 (17.5) | 6 (7.5) | 0.194 |
BUN (mg/dL, mean ± SD) | 20.1 ± 11.8 | 17.2 ± 7.4 | 0.189 |
Creatinine (mg/dL, mean ± SD) | 1.6 ± 2.2 | 1.5 ± 1.0 | 0.113 |
Hyperlipidemia (n, %) | 8 (10.0) | 12 (15.0) | 0.519 |
Previous AMI (n, %) | 2 (2.5) | 4 (5.0) | 0.241 |
PCI history (n, %) | 16 (20.0) | 18 (22.5) | 0.790 |
Acute coronary syndrome | |||
Unstable angina (n, %) | 26 (32.5) | 24 (30.0) | 0.999 |
STEMI (n, %) | 2 (2.5) | 10 (12.5) | 0.201 |
NSTEMI (n, %) | 20 (25.0) | 16 (20.0) | 0.790 |
LVEF (%, mean ± SD) | 56.2 ± 14.0 | 53.1 ± 13.7 | 0.757 |
LM disease (n, %) | 16 (20.0) | 22 (27.5) | 0.708 |
Hemoglobin (g/dL, mean ± SD) | 12.4 ± 2.2 | 12.4 ± 2.4 | 0.507 |
Hematocrit (%, mean ± SD) | 36.3 ± 6.7 | 36.8 ± 7.0 | 0.436 |
Platelet (10–3/μL, mean ± SD) | 251 [101, 340] | 282 [113, 376] | 0.480 |
Prothrombin time (INR, mean ± SD) | 1.0 ± 0.1 | 1.0 ± 0.1 | 0.270 |
aPTT (mean ± SD) | 49.8 ± 21.3 | 44.8 ± 17.4 | 0.094 |
Creatinine (mg/dL, mean ± SD) | 1.0 ± 0.5 | 1.1 ± 1.4 | 0.162 |
Preoperative medications | |||
Aspirin (n, %) | 80 (100) | 80 (100) | - |
Heparin, intravenous (n, %) | 46 (57.5) | 36 (45.0) | 0.371 |
β-blocker (n, %) | 20 (25.0) | 22 (27.5) | 0.525 |
ACEI/ARB (n, %) | 6 (7.5) | 8 (10.0) | 0.226 |
Calcium channel blocker (n, %) | 16 (20.0) | 16 (15.0) | 0.428 |
Statins (n, %) | 40 (50.0) | 32 (40.0) | 0.311 |
Nitrates (n, %) | 2 (2.5) | 4 (5.0) | 0.573 |